Myovant Sciences Ltd. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 12 rows in 2017. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-08-18: Reporting owner Sebelius Kathleen; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-08-18: Reporting owner DeVeydt Wayne S; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-08-18: Reporting owner Curran Terrie; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-08-18: Reporting owner Altmeyer Mark; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-08-18 | Sebelius Kathleen Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,500 22,500 owned after | $13.14 exercise price | 2017-10-20 | |
| 2017-08-18 | DeVeydt Wayne S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,500 22,500 owned after | $13.14 exercise price | 2017-10-20 | |
| 2017-08-18 | Curran Terrie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,500 22,500 owned after | $13.14 exercise price | 2017-10-20 | |
| 2017-08-18 | Altmeyer Mark Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,500 22,500 owned after | $13.14 exercise price | 2017-10-20 | |
| 2017-08-15 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +260,000 260,000 owned after | $10.60 exercise price | 2017-08-17 | |
| 2017-07-17 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +310,000 310,000 owned after | $11.30 exercise price | 2017-07-18 | |
| 2017-05-15 | Altmeyer Mark Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,154 11,154 owned after | $12.68 exercise price | 2017-05-17 | |
| 2017-05-15 | Sebelius Kathleen Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,154 11,154 owned after | $12.68 exercise price | 2017-05-17 | |
| 2017-05-15 | DeVeydt Wayne S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,154 11,154 owned after | $12.68 exercise price | 2017-05-17 | |
| 2017-05-15 | Curran Terrie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,154 11,154 owned after | $12.68 exercise price | 2017-05-17 | |
| 2017-05-15 | Seely Lynn Director, Officer (Principal Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +400,000 400,000 owned after | $12.68 exercise price | 2017-05-17 | |
| 2017-05-15 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $12.68 exercise price | 2017-05-17 |